Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities, calculated as total liabilities divided by total asset. Genetic Technologies's Total Liabilities for the quarter that ended in Jun. 2024 was $2.89 Mil. Genetic Technologies's Total Assets for the quarter that ended in Jun. 2024 was $4.11 Mil.
Therefore, Genetic Technologies's Liabilities-to-Assets Ratio for the quarter that ended in Jun. 2024 was 0.70.
Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.
Genetic Technologies Liabilities-to-Assets Related Terms
Genetic Technologies Liabilities-to-Assets Historical Data
* Premium members only.
The historical data trend for Genetic Technologies's Liabilities-to-Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GNTLF vs LDDD, NOTV, ATLN: Liabilities-to-Assets Comparison
For the Diagnostics & Research subindustry, Genetic Technologies's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genetic Technologies Liabilities-to-Assets vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Genetic Technologies's Liabilities-to-Assets distribution charts can be found below:
* The bar in red indicates where Genetic Technologies's Liabilities-to-Assets falls into.
Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.
Genetic Technologies's Liabilities-to-Assets Ratio for the fiscal year that ended in Jun. 2024 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genetic Technologies (GNTLF) has a Liabilities-to-Assets of 0.70 as of Jun. 2024. Liabilities-to-Assets equals total liabilities divided by total assets. It measures financial leverage. View historical data on Genetic Technologies and its competitors.
Is Genetic Technologies' Liabilities-to-Assets too high?
Genetic Technologies' current Liabilities-to-Assets is 0.70. Overall, Genetic Technologies has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Genetic Technologies' Liabilities-to-Assets compare to LDDD and NOTV?
Genetic Technologies' Liabilities-to-Assets of 0.70 can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Liabilities-to-Assets for a Medical Diagnostics & Research company?
A good Liabilities-to-Assets depends on the Medical Diagnostics & Research industry context. However, Liabilities-to-Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Liabilities-to-Assets mean?
A high Liabilities-to-Assets can signal that a stock is expensive relative to its fundamentals. Liabilities-to-Assets equals total liabilities divided by total assets. It measures financial leverage. View historical data on Genetic Technologies and its competitors. Genetic Technologies's current Liabilities-to-Assets is 0.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genetic Technologies stock overvalued right now?
Genetic Technologies (GNTLF) has a current Liabilities-to-Assets of 0.70. The current Liabilities-to-Assets is 0.70. Genetic Technologies' overall GF Score™ is 18/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Liabilities-to-Assets calculated?
Liabilities-to-Assets is calculated from a company's financial statements. For Genetic Technologies (GNTLF), the current Liabilities-to-Assets is 0.70 as of Jun. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Genetic Technologies Ltd is an Australia-based molecular diagnostics company that offers predictive testing and assessment tools to help physicians proactively manage women's health. The company has developed BREVAGenplus which is a clinically validated risk assessment test for non-hereditary breast cancer. It also provides genetic testing services including medical testing, animal testing, forensic testing, and plant testing. The company markets BREVAGenplus to healthcare professionals in breast healthcare and imaging centers, as well as to obstetricians/ gynecologists (OBGYNs) and breast cancer risk assessment specialists. The majority of the company's revenue is generated from Australia and the United States. The group has two operating segments: EasyDNA and GeneType/Corporate.
18GF Score
Get the complete analysis for GNTLF
Liabilities-to-Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GNTLF has been successfully added to your 
